A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma

Cancer Research

Volumn 56, Issue 4, 1996, Pages 689-693

  Righetti, Sabina C ^a   Della Torre, Gabriella ^a   Pilotti, Silvana ^a   Ménard, Sylvie ^a   Ottone, Francesca ^a   Colnaghi, Maria I ^a   Pierotti, Marco A ^a   Lavarino, Cinzia ^a   Cornarotti, Mariagrazia ^a   Oriana, Saro ^a   Böhm, Silvia ^a   Bresciani, Gian Luigi ^a   Spatti, Giambattista ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IFOSFAMIDE; MITOXANTRONE; PROTEIN P53;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOSENSITIVITY; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; OVARY CARCINOMA; PRIORITY JOURNAL;

ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CODON; EXONS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRONS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POINT MUTATION; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13344249778     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Neijt, J. P. Advances in the chemotherapy of gynecologic cancer Curr Opin. Oncol., 6. 531-538, 1994.
2. McGuire, W. P , and Rowinsky, E. K. Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy. Semin. Oncol., 18 255-269, 1991
3. Thigpen, J T , Bertelsen, K , Eisenhauer, E A , Hacker, N. F., Lund, B., and Sessa, C Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol., 4: S35-S40, 1993.
4. Hamilton, T C., O'Dwyer, P. J , and Ozols, R. F. Platinum analogues in preclinical and clinical development. Curr Opin. Oncol., 5. 1010-1016, 1993.
5. Dive, C., and Hickman, J A Drug-target interactions: only the first step in the commitment to a programmed cell death. Br. J Cancer, 64. 192-196, 1991.
6. Fisher, D. E. Apoptosis in cancer therapy crossing the threshold. Cell, 78: 539-542, 1994.
7. Williams, G. T , and Smith, C. A. Molecular regulation of apoptosis: genetic controls on cell death Cell, 74. 777-779, 1993.
8. Kastan, M. B., Canman, C. E., and Leonard, C. J. p53, cell cycle control and apoptosis implications for cancer. Cancer Metastasis Rev , 14 3-15, 1995.
9. Boente, M. P., Hurteau, J , Rodriguez, G. C., Bast, R C , and Berchuck, A. The biology of ovarian cancer. Curr Opin. Oncol., 5 900-907, 1993
10. Kohler, M. F., Marks, J. R , Wiseman, R. W , Jacobs, I J., Davidoff, A. M , Clarke-Pearson, D. L., Soper, J T., Bast, R. C , and Berchuck, A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer J Natl Cancer Inst., 85: 1513-1519, 1993
11. Perego, P., Giarola, M , Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T , Reed, J C., and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 56: 556-562, 1996.
12. Di Re, F., Böhm, S., Oriana, S., Spatti, G. B., Pirovano, C., Tedeschi, M., and Zunino, F. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol , 4: 55-61, 1993.
13. Donghi, R., Longoni, A., Pilotti, S., Mtchieli, P., Della Porta, G., and Pierotti, M. A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland J. Clin Invest., 91: 1753-1760, 1993.
14. Picksley, S. M., Vojtesek B , Sparks, A , and Lane, D P Immunochemical analysis of the interaction of p53 with MDM2. fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene, 9: 2523-2529, 1994.
15. Yewdell, J W , Gannon, J. V., and Lane, D. P Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol., 59: 444-452, 1986
16. Milner, J. Forms and functions of p53. Semin. Cancer Biol., 5: 211-219, 1994.
17. Cattoretti, G., Pileri, S., Parravicini, C , Becker, M. H. G , Poggi, S., Bifulco, C., Key, G., D'Amato, L., Sabattini, E., Feudale, E , Reynolds, F., Gerdes, J , and Rilke, F. Antigen unmasking on formalin-fixed, paraffin embedded tissue section. J. Pathol., 71: 83-98, 1993
18. Daly, L. E., Bourke, G. J , and McGilvray, J. Interpretation and uses of medical statistics, Ed. 4. Oxford: Blackwell, 1991.
19. Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M , Bell, D. A., and Yandell, D. W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl Acad. Sci. USA, 90: 4961-4965, 1993.
20. Kappes, S., Milde-Langosch, K , Kressin, P , Passlack, B., Dockhorn-Dworniczak, B., Rohlke, P., and Loning, T. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J. Cancer, 64: 52-59, 1995.
21. Vogelstein, B., and Kinzler, K. W. X-rays strike p53 again. Nature (Lond), 370. 174-175, 1994.
22. van der Zee, A. G. J., Hollema, H., Suurmeijer, A. J. H., Krans, M., Sluiter, W. J., Willemse, P. H. B., Aalders, J G., and de Vries, E. G. E. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol., 13: 70-78, 1995.
23. Levesque, M. A., Katsaros, D., Yu, H., Zola, P., Sismondi, P., Giardina, G., and Diamandis, E P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer (Phila.), 75. 1327-1338, 1995.
24. Lowe, S. W., Ruley, H. E , Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
25. Nabeya, Y., Loganzo, F., Maslak, P., Lai, L., De Oliveira, A. R., Schwartz, G. K , Blundell, M. L., Altorki, N. K , Kelsen, D. P., and Albino, A. P. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer, 64: 37-46, 1995
26. Greenblatt, M. S., Bennett, W. P , Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
27. Hartmann, A., Blaszyk, H., McGovern, R. M., Schroeder, J. J., Cunningham, J., De Vries, E M. G., Kovach, J. S., and Sommer, S. S. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancer. Oncogene, 10: 681-688, 1995.
28. Park, D. J., Nakamura, H., Chumakov, A. M., Said, J. W., Miller, C. W., Chen, D. L., and Koeffler, H. P. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene, 9: 1899-1906, 1994.
29. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J-M., Wang, Z., Friedberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A , Weeda, G., Hoeijmakers, J. H. J., Forrester, K., and Harris, C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10: 188-195, 1995.
30. Borresen, A-L., Andersen, T. I., Eyfjord, J. E., Cornelis, R. S , Thorlacius, S., Borg, A., Johansson, U., Theillet, C , Scherneck, S , Hartman, S., Cornelisse, C. J., Hovig, E., and Devilee, P. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes & Cancer, 14: 71-75, 1995.
31. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.
32. Milner, J. DNA damage, p53 and anticancer therapies. Nature Med., 1: 879-890, 1995.
33. Van der Zee, A. G. J., Hollema, H. H., de Bruijn, H. W. A., Willemse, P. H. B., Boonstra, H., Mulder, N. H , Aalders, J. G., and de Vries, E. G. E. Cell biological markers of drug resistance in ovarian carcinoma Gynecol. Oncol., 58: 165-178, 1995.